SAN MATEO, Calif., June 19, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced it has received two notices of allowance from the United States Patent and Trademark Office (USPTO) for patents covering NGX-1998, the Company's next generation liquid formulation of prescription strength capsaicin.